You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Y2 and Y4 Agonists in Obesity

    SBC: P2D, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The purpose of the proposed studies is to assess the feasibility of developing a novel Neuropeptide Y (NPY) obesity treatment. Extensive preclinical and clinical studies indicate that NPY receptors are important mediators of appetite and obesity. The proposed Specific Aims will determine if chronic treatment with selective NPY Y2 or Y4 receptor agonists demonst ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Venous Thromboembolism Risk Marker Assay

    SBC: Gamma Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The application's broad, long-term objectives are to develop a rapid, high-throughput clinical assay for 3' fibrinogen that will be used to assess the risk of a patient developing venous thromboembolism. This assay will guide clinical management, particularly the use of long-term anticoagulant therapy for patients. The utility of this assay will be the identifi ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Use Mobile Devices and Cloud Computing Platforms for Real-time Data Solutions in

    SBC: INVENUX, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a botanical drug for use in children that prevents theinexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Unique Antimicrobial Catheter to Prevent Urinary Tract Infections

    SBC: NORTHWEST MEDIA, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): In this Phase I we will develop and evaluate the first unit of an online serious game for foster and primary parents of neglected children. The goal of the training is to learn how parents in these two historically compartmentalized roles can improve their parenting by working cooperatively. Research shows that cross-training strategies can optimize the chances ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Transportation Vehicle Waste Heat Recovery System

    SBC: MMPG LLC            Topic: 101FT1

    A one-cylinder diesel engine will be modified to achieve a 20% to 40% improvement in fuel efficiency. This will be accomplished by insulating the interior of the combustion chamber with a proprietary thermal insulating material. Heat normally transferred to the engine coolant through the walls of the head, cylinder and piston will be retained within the combustion chamber where it is available t ...

    SBIR Phase I 2010 Department of Transportation
  6. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: SUVICA INC            Topic: NCI

    The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HN ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Throughmask ElectroEtching for Cost-Effective Nitinol Stent Fabrication

    SBC: Faraday Technology, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Description Faraday Technology, Inc. proposes to develop the Faradayic ElectroEtching Process, based on pulsed electrolytic through-mask etching of nitinol stents, for rapid stent fabrication while maintaining pattern fidelity in a neutral, aqueous, non-toxic electrolyte. This process will enable stent manufacturing while minimizing process control difficultie ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. The Simultaneous Acquisition of Auditory Transient and Steady State Evoked Potent

    SBC: INTELLIGENT HEARING SYSTEMS CORP            Topic: NIDCD

    DESCRIPTION (provided by applicant): This project aims to develop a device capable of acquiring transient and steady state auditory evoked potenlatials (AEPs) simultaneously using an efficient and advanced processing technique. The proposed technique willbe implemented as a software module on Intelligent Hearing Systems' (IHS) evoked potential system platform. Auditory Transient Responses (AT ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Protein C Activator for Myocardial Ischemia

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Rapidly progressing occlusion of the coronary artery and the subsequent acute myocardial ischemia is the most prevalent primary cause of acute myocardial infarction (AMI) and death in the United States. Early recanalization and antithrombotic therapy promotes reperfusion and improves outcomes when administered before completion of the infarct. However, most he ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic factor XI blockade for sepsis

    SBC: ARONORA INC            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR grant will support the initial commercial development of a single dose injectable biological product candidate, recombinant humanized anti-factor XI monoclonal therapeutic anticoagulant antibody, towards an investigational new drug (IND) application. The lead indication is severe bacterial sepsis, which is among the leading causes of mortality ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government